Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-040XC vs Single Component Therapies in Hypertension and Hyperlipidemia
NCT01541943Phase 3Completed
- Sponsor
- HanAll Biopharma
- Start
- Mar 2012
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atorvastatin and losartan in essential hypertension and hyperlipidemia (4 arms), sponsored by HanAll Biopharma. Primary endpoints: Change from baseline in Sitting Diastolic Blood Pressure at 8 weeks and Percent change from baseline in LDL-Cholesterol at 8 weeks. Started Mar 2012; status: completed.
02
Drugs
atorvastatinlosartan
03
Conditions
essential hypertensionhyperlipidemia
Beyond the preview
Go deeper on NCT01541943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01541943.